From Earlier: Pacira Says Statistical Significance Seen at Primary Endpoints

Pacira Pharmaceuticals, Inc. PCRX today announced topline results from the first completed IMPROVE study in its prospective Phase 4 clinical program. The study was designed to compare the difference in three primary endpoints—cost, opioid consumption and hospital length of stay (LOS)—between one group of patients receiving a standard opioid-based postsurgical pain management regimen and a second group of patients receiving EXPAREL^® (bupivacaine liposome injectable suspension) as the foundation of an opioid-sparing multimodal regimen.